在ALK阳性非小细胞肺癌与alectinib耐药性肺癌中,alectinib在进展后的延续
Yimeng Li1, Zhanpeng Hao1, Yuyan Ma1
1Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Translational lung cancer research
|February 26, 2024
概括
继续使用alectinib与其他疗法显示,对ALK阳性NSCLC患者发展抗药性的NSCLC患者有希望. 这种方法可以改善生存结果,而不是在疾病进展后切换治疗方法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿列克提尼布是治疗形淋巴瘤激酶阳性非小细胞肺癌 (NSCLC) 的关键治疗方法.
- 很大一部分患者对alectinib产生耐药性,需要进一步的治疗策略.
- 关于在NSCLC中继续使用alectinib后进展的数据有限.
研究的目的:
- 评估ALK阳性NSCLC患者在疾病进展后继续使用alectinib结合其他疗法的疗效和安全性.
- 确定可能从这一策略中受益的潜在患者群体.
主要方法:
- 在中国对15名ALK阳性NSCLC患者进行了回顾性队列研究 (2019-2022).
- 患者在寡头进展或中枢神经系统 (CNS) 进展后继续接受alectinib以及其他疗法.
- 评估结果包括中位数无进展生存期 (mPFS),客观反应率 (ORR),中位数整体生存期 (mOS) 和不良事件 (AE).
主要成果:
- 持续的alectinib治疗显示PFS的中位数为8个月 (95%CI:4到NA).
- 在研究的队列中,客观反应率 (ORR) 为46.7%.
- 副作用是最小的,只有一个患者经历了2级肝酶升高.
结论:
- 继续使用alectinib与其他疗法是ALK阳性NSCLC患者的有效和安全,这些患者有寡进或中枢神经系统进展.
- 与立即切换到替代ALK-TKI相比,这种策略可能会提供更好的生存益处.
关键词:
有ALK阳性的人.阿莱克提尼布 (Alectinib) 是一种药物.性淋巴瘤激酶 - 铁氨酸激酶抑制剂 (ALK-TKI)非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.电阻的电阻是指电阻的电阻更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166